

Hueber, Anne-Odile, PhD

CNRS UMR 7277 / INSERM UMR 1091 / UNS
Bat Sc naturelles-Parc Valrose - 06108 Nice cedex 2
☎ +33 (0) 492 07 6447 / ✉ hueber@unice.fr
<http://ibv.unice.fr/EN/equipe/hueber.php>



French, born April 26th, 1968

Research Director at Inserm (Institut national de la santé et de la recherche médicale)
PhD, PI

EDUCATIONS/TRAINING

- Aix-Marseille University HDR (habilitation) 2001
- Imperial cancer research Fund, London, UK Postdoc 1995-1999
- Aix-Marseille University PhD 1995

POSITIONS

- 2001-present **Group leader** at iBV (ATIP, LNCC), Nice, France
Senior Inserm Investigator (tenured position)
- 1999-2001 Junior Inserm Investigator (tenured position P.Golstein's lab), CIML, Marseille, France
- 1997-1999 Research ICRF Fellow, ICRF, London, UK (Post-doctoral position in G. Evan's lab)
- 1995-1997 Research EMBO Fellow, ICRF, London, UK (G Post-doctoral position in G. Evan's lab)
- 1991-1995 PhD Fellow (Research French ministry), CIML (immunology center, Marseille, France)

PRIZES/AWARDS

- Recipient of a Contrat d'Interface CHU-Inserm (2005-2010); Prime d'excellence scientifique (2009-20012)
- 2006-2011, Equipe Labélisée Ligue (LNCC)
- 2002, Cancerology prize, Fondation Rosen, French Medical Foundation (FRM)
- 2001, ATIP CNRS granted

EXPERTISES, COMMITTEES, and RESPONSABILITIES

- Scientific council member of the University of Nice Sophia Antipolis (since 2012)
- Academic council member of the University of Nice Sophia Antipolis (since 2014)
- Steering committee member of the ECOD network (since 2015)
- Executive board member, Inserm correspondent of the university cote d'Azur (UCA) (since 2015)
- Scientific council member of Canceropole PACA (2004-2011)
- Nominated member of the scientific evaluation committee of ARC (French association pour la Recherche sur le cancer)
- Scientific council member of the University Hospital biobank (2007-2011)
- Co-leader of the "functional genomics" axis-Canceropole PACA (2007-2012)
- Scientific evaluation committee (president) AERES (2011)
- Scientific ethic committee member University of Nice (2012-2016)
- Scientific council member of the Clinical research center (CRC) Hospital (2012-2016)
- Team of the Labex Signallife network (ANR; laboratory of excellence; axis 1&4) (2012-2019)
- International scientific journal ad hoc reviewer (Plos One, Cell Death&Differentiation, Cell Death&Disease, Cancer Research, Scientific Reports)
- National and international grants ad hoc reviewer (LNCC, Aviesan, ITMO Cancer, Inserm, regions, hungarian scientific research grant).
- Scientific coordinator of the iBV flow cytometry facility (since 2012)
- Scientific coordinator of the iBV animal facility (2004-2011)
- Scientific coordinator of the iBV Biochemistry facility (2008-2012)
-

PATENTS/LICENSES

15/06/2015 Method for predicting the response to a TNFSF6-influenced cancer treatment and for predicting resistance to a cancer treatment. (**PCT/EP2016/063390**) (Chakrabandhu, K., Hueber, AO).

MAIN INTERESTS

The main scientific interest of my team is to understand the roles of death receptors belonging to the tumor necrosis factors receptors in cancer biology, with the focus on the Fas (TNFRSF6/CD95) signalling in the control of life and death of cells in relation to cancer therapies. Our main research accomplishments during the last five years include: 1. the delineation of the regulation of Fas-mediated cell death in the haematological context and its clinical impact and 2. the description of Fas multi-signaling switch regulation in cancer and its application in cancer therapy. Our work significantly contributed to a clearer understanding about how the Fas signaling is shifted from tumor-suppressing to tumor-driving mode, as well as presented the means to appropriately take control of the duality of Fas signaling in different pathological contexts in order to increase therapeutic success. In continuation of our previous accomplishment, our research prospect is aimed to achieve a deeper understanding in the versatility of Fas signaling and to clinically apply the knowledge in CRC therapy. In particular, we will dissect the control of Fas signaling in level of protein modifications, membrane receptor crosstalk, and multi-cellular regulation. The findings from our study which will include drug targets, molecular tools, and novel biologics are to be developed into applications at clinical and industrial level.

SELECTED PUBLICATIONS (out of > 60 publications)

- Chakrabandhu, K., Huault, S. and Hueber, AO. **Methods Mol Biol**. 2017;1557:173-188
- Rossin, A., and Hueber, AO. **Methods Mol Biol**. 2017;1557:189-198.
- Chakrabandhu, K., and Hueber, AO. **Frontiers in Immunology** (2016) Oct 17;7:429.
- Chakrabandhu, K., Huault, S., Durivault, J., Lang, K., Ta-Ngoc, Ly., Doma, E., Bole, A., Gerard, J-P., Pierres, M., Hueber, A-O. **PLoS Biology**. (2016) 14(3):e1002401.
- Andersen, D.S., Colombani, J., Palmerini, V., Chakrabandhu, K. Boone, E. Rothlisberger, M., Toggweiler, J., Basler, K., Mapelli, M., Hueber, A.O., Leopold, P. **Nature** (2015) 522(7557):482-6.
- Rossin, A., Durivault, J., Chakhtoura-Fegali, T., Hueber, A.O. **Cell Death Differ**. (2015) 4:643-53
- Zhu, L., Derijard, B., Chakrabandhu, K., Wang, B.S., Chen, H.Z. Hueber, A.O. **Cancer Letters**, (2014) 28;354(2):355-64.
- Legros L, Guilhot J, Huault S, Mahon FX, Preudhomme C Guilhot F, Hueber AO. **Leukemia Research**, (2014) 38(6):662-5.
- Hueber, AO and Koncz, G. 2012. **Frontiers in Immunology**;3:207.
- Koncz, G., Hancz, A., Chakrabandhu, K., Gogolak, P., Rajnavolgyi, E., Hueber, AO. **J Immunol**. (2012) 189(6):2815-23.
- Legros, L, Ebran, N, Stebe, E, Rousselot, P, Rea, D, Cassuto, JP, Mahon, FX, Hueber, AO. 2011. **J of Immunotherapy**. 35(2):154-8.
- Guardiola-Serrano, F., Rossin, A., Cahuzac, N., Lückerrath, K., Melzer, I., Mailfert, S., Marguet, D., Zörnig, M., Hueber, AO. **Cell Death&Disease**. (2010); 1(10)-e88.
- Rossin, A Kral, R., Lounnas, N, Chakrabandhu, K.; Mailfert S., Marguet D., Hueber, AO. **Exp Cell Res**. (2010). 316(9):1513-22.
- Rossin, A., Derouet, M, Abdel Sater, F; Hueber, A-O. **Biochem J**. (2009). 419(1):185-94.
- Chakrabandhu, K., Huault, S, Hueber, A-O. **FEBS Lett**. (2008). 582(30):4176-84
- Maise, C., Rossin, A, Cahuzac, N, Paradisi, A., Klein, C., Haillot, M-L., Hérincs, Z., Mehlen, P, Hueber, A-O. **Exp Cell Res**. (2008). 314(14):2544-52.
- Chakrabandhu, K., Huault, S., Garmy, N., Stebbe, E., Mailfert, S., Marguet, D., Fantini, J, Hueber, A-O. **Cell Death Diff**, (2008). (12):1824-37.
- Roque-Navarro, L., Chakrabandhu, K., de León, J., Rodríguez, S., Toledo, C., Carr, A., Mateo de Acosta, C., Hueber, A.O., Pérez, R. **Molecular Cancer therapeutics** (2008). 7:2033-41.

- Koncz, G., Herekes C., Chabrandhu, K., Hueber, AO. **Cell Death Diff**, (2008). (3):494-503.
- Kirkin, V., Cahuzac, N., Friedmann, E., Mateus SB, Wels, WS, Martoglio, B., Hueber, AO.*, M. Zörnig*, **Cell Death Diff**, (2007). 9:1678-87.
- Peter, ME., Budd, RC., Desbarats, J., Hedrick, SM., Hueber, AO., Newell, MK., Owen, LB., Pope, RM., *et al* . **Cell**. (2007). 129(3):447-50.
- K. Chabrandhu, Z. Hérincs, S. Huault, D. Britta, P. Ling, F. Conchonnaud, D. Marguet, H-T He, A-O Hueber. **The EMBO J**, (2007). 26(1):209-20.
- Leal-Sanchez, J., Couzinet, A., Rossin, A., Dost, B., Luci, C., Anjuere, F., Stebe, E., Hancock, D., Hueber, A-O. **Cell Death Differ**, (2007). 4:795-806.
- Furne, C., Corset, V., Hérincs, Z., Cahuzac, N., Guix, C., Hueber, A-O.*, and Mehlen, P*. **Proc Natl Acad Sci U S A**. (2006). 103(11):4128-33.
- Cahuzac, N., Baum, W., Kirkin, V., Conchonaud, F., Marguet, D., Janssen, O., Zörnig, M*, Hueber, A-O*. **Blood**. (2006). 107(6):2384-91.
- Hérincs, Z., Corset, V., Cahuzac, N., Furne, C., Castellani, V., Hueber, A-O*, Mehlen, P*. **J. of Cell Science** (2005). 118:1687-92.
- Raoul#, C., Barthelemy#, C., Couzinet, A., Hancock, D., Pettmann, B., Hueber, A-O. **J. of Neurobiology** (2005) 5;62(2):178-88.
- Hueber, A-O., Bösser, S., and Zörnig, M. **International Journal of Cancer**. (2004) 10;112(3):536-40.
- Ugolini, G., Raoul, C., Ferri, A., Haenggeli, C., Yamamoto, Y., Salaün, D., Henderson, C. E., Kato, A, Pettmann, B*, Hueber, A-O*, **The Journal of Neuroscience** (2003) 23(24):8526-31.
- Hueber, A-O., **Cell Death Differ** (2003) 10, 7.
- Hueber, AO, Bernard, A-M. Z. Hérincs, A. Couzinet, and H-T He. **EMBO Reports** (2002) 3(2) 190-196.
- Rudolph, B., Hueber, A.O., Evan, G. **Oncogene** (2000) 20(10):1164-75.
- Zörnig, M., Hueber, A.O, Evan, G.E. In **Molecular Basis of Cancer**; 2nd edition, (2000) Mendelsohn, Howley, Israel&Liotta, eds.
- Rudolph, B., Hueber, A.O., Evan, G. **Oncogene** (2000) 19(15):1891-1900.
- Hueber, A.O. **Nature Cell Biology** (2000) 2, 23-25.
- Hueber, A.O*, Zörnig*, M., Bernard, A.M., Chautan, M., and Evan, G. **J Biol. Chem.** (2000) 275, 10453-10462.
- Juin, P., Hueber, A.O., Littlewood, T., and Evan, G. **Genes Dev.** (1999) 13, 1367-1381.
- Hueber, A.O. and Evan, G.I. **Trends. Genet** (1998) 14, 364-367.
- Rohn, J.L., Hueber, A.O., McCarthy, N.J., Lyon, D., Navarro, P., Burgering, B.M., and Evan, G.I. **Oncogene** (1998) 17, 2811-18.
- Zörnig, M*, Hueber, A.O*., Evan, G. **Current Biology** (1998). 8, 467-470.
- Hueber, A.O., Zörnig, M., Lyon, D., Suda, T., Nagata, S., and Evan, G.I. **Science** (1997) 278, 1305-1309.
- Hueber, A.O*, Bernard, A.M.*, Battari, C.L., Marguet, D., Massol, P., Foa, C., Brun, N., Garcia, S., Stewart, C., Pierres, M., He, H.T. **Current Biology** (1997) 7, 705-708.
- Hueber, A.O., Raposo, G., Pierres, M., He, H.T. **J. Exp. Med.** (1994) 179, 785-796.
- Hueber, A.O., Pierres, M., He, H.T. **J. of Immunology**. (1992) 148, 3692-3699.